|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2007
Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes
1 Dept of Medicine, University of Auckland, and 2 Respiratory Services, Green Lane Hospital, Auckland, New Zealand.
CORRESPONDENCE: R. P. Young, Dept of Medicine, Auckland Hospital, Private Bag 92019, Auckland, New Zealand. Fax: 64 96310711. E-mail: roberty{at}adhb.govt.nz
Keywords: Baseline risk, chronic obstructive pulmonary disease, epidemiology, lung function, premature death, spirometry
Received: February 22, 2007
Accepted July 22, 2007
The clinical utility of spirometric screening of asymptomatic smokers for early signs of air flow limitation has recently come under review. The current authors propose that reduced forced expiratory volume in one second (FEV1) is more than a measure of airflow limitation, but a marker of premature death with broad utility in assessing baseline risk of chronic obstructive pulmonary disease (COPD), lung cancer, coronary artery disease and stroke, collectively accounting for 70–80% of premature death in smokers.
Reduced FEV1 identifies undiagnosed COPD, has comparable utility to that of serum cholesterol in assessing cardiovascular risk and defines those smokers at greatest risk of lung cancer. As such, reduced FEV1 should be considered a marker that identifies smokers at greatest need of medical intervention.
Smoking cessation has been shown to attenuate FEV1 decline and, if achieved before the age of 45–50 yrs, may not only preserve FEV1 within normal values but substantially reduce cardiorespiratory complications of smoking.
Recent findings suggest inhaled drugs (bronchodilators and corticosteroids), and possibly statins, may be effective in reducing morbidity and mortality in patients with chronic obstructive pulmonary disease. The current authors propose that spirometry has broad utility in identifying smokers who are at greatest risk of cardiorespiratory complications and greatest benefit from targeted preventive strategies, such as smoking cessation, prioritised screening and effective pharmacotherapy.
This article has been cited by other articles:
|
|
 |
|
  E. Calabro, G. Randi, C. La Vecchia, N. Sverzellati, A. Marchiano, M. Villani, M. Zompatori, R. Cassandro, S. Harari, and U. Pastorino Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes Eur. Respir. J., January 1, 2010; 35(1): 146 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Young, R. Hopkins, and T. E. Eaton Pharmacological actions of statins: potential utility in COPD Eur. Respir. Rev., December 1, 2009; 18(114): 222 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Newman, M. C. Sachs, A. M. Arnold, L. P. Fried, R. Kronmal, M. Cushman, B. M. Psaty, T. B. Harris, J. A. Robbins, G. L. Burke, et al. Total and Cause-Specific Mortality in the Cardiovascular Health Study J Gerontol A Biol Sci Med Sci, December 1, 2009; 64A(12): 1251 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Laghi, N. Adiguzel, and M. J. Tobin Endocrinological derangements in COPD Eur. Respir. J., October 1, 2009; 34(4): 975 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R P Young, R J Hopkins, B A Hay, M J Epton, G D Mills, P N Black, H D Gardner, R Sullivan, and G D Gamble A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers Postgrad. Med. J., October 1, 2009; 85(1008): 515 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Lange, M. Mulholland, and M. E. Kreider Spirometry: Don't Blow It! Chest, August 1, 2009; 136(2): 608 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Young, R. J. Hopkins, T. Christmas, P. N. Black, P. Metcalf, and G. D. Gamble COPD prevalence is increased in lung cancer, independent of age, sex and smoking history Eur. Respir. J., August 1, 2009; 34(2): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R P Young, R Hopkins, and T E Eaton Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence Postgrad. Med. J., August 1, 2009; 85(1006): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Engstrom, M. Gerhardsson de Verdier, M. Dahlback, C. Janson, and L. Lind BP Variability and Cardiovascular Autonomic Function in Relation to Forced Expiratory Volume: A Population-Based Study Chest, July 1, 2009; 136(1): 177 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Leone, D. Courbon, F. Thomas, K. Bean, B. Jego, B. Leynaert, L. Guize, and M. Zureik Lung Function Impairment and Metabolic Syndrome: The Critical Role of Abdominal Obesity Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. MacNee, J. Maclay, and D. McAllister Cardiovascular Injury and Repair in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2008; 5(8): 824 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Young, R. J. Hopkins, B. A. Hay, M. J. Epton, P. N. Black, and G. D. Gamble Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur. Respir. J., November 1, 2008; 32(5): 1158 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Complex chronic comorbidities of COPD Eur. Respir. J., January 1, 2008; 31(1): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |